Valbenazine and vitamin E are the most effective treatments for tardive dyskinesia, with valbenazine showing the strongest effect size in recent studies. Transcranial direct current stimulation shows ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Incidence rates of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A priori hypothesized associations between incident TDD and other dopamine proxies (e.g ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

A review article by veterinary specialist and associate professor at Utrecht University Paul Mandigers and colleagues brings together knowledge on the movement disorder paroxysmal dyskinesia (PD), ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...